Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2576 - Clinical relevance of circulating MACC1 and S100A4 transcripts in serum of ovarian cancer patients

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Cancer Biology

Tumour Site

Ovarian Cancer

Presenters

Pauline Wimberger

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

P. Wimberger1, T. Link1, P. Herrmann2, D. Kobelt2, Y. Vassileva1, F. Kerstin3, J.D. Kuhlmann1, U. Stein2

Author affiliations

  • 1 Department Of Gynecology And Obstetrics, Technische Universität Dresden, 01307 - Dresden/DE
  • 2 Dept. Translational Oncology Of Solid Tumors, Charité - Universitätsmedizin Berlin, 10117 - Berlin/DE
  • 3 Drk-blood Donor Service, ITM Plauen, 01307 - Dresden/DE
More

Resources

Abstract 2576

Background

Metastasis-associated in colon cancer 1 (MACC1) and S100 calcium binding protein A4 (S100A4) promote metastasis. Their overexpression in the tumor was proposed as a prognostic and/or predictive biomarker for a variety of solid malignancies, including ovarian cancer. However, clinical relevance of circulating MACC1 and S100A4 transcripts as blood-based biomarkers for ovarian cancer is unknown. Therefore, the objective of our study was to systematically track serum levels of both transcripts in the course of surgery and adjuvant therapy and to analyze their clinical relevance for ovarian cancer.

Methods

The levels of MACC1 and S100A4 transcripts were analyzed in a total of 318 serum samples from 79 ovarian cancer patients (thereof 80% FIGO III or IV), including samples at primary diagnosis and at 4 follow-up time points in the course of treatment. MACC1 was relatively quantified by RT-qPCR and S100A4 was absolutely quantified by digital droplet PCR.

Results

MACC1 and S100A4 transcripts were significantly elevated in serum of ovarian cancer patients, compared to healthy controls (p = 0.024;p<0.001) and showed a highly concordant (CA125 independent) dynamic in the course of treatment. Higher levels of MACC1 and S100A4 at primary diagnosis paralleled advanced disease (p = 0.023;p=0.004) and predicted ineffective primary debulking surgery with no achievement of a macroscopically complete tumor resection (p = 0.011;p=0.006). Moreover, higher levels of MACC1 and S100A4 at primary diagnosis indicated poor DFS (p = 0.0035; p = 0.0019) and OS (p < 0.001;p=0.001).

Conclusions

This is the first liquid biopsy approach, systematically analyzing MACC1 and S100A4 transcripts in ovarian cancer and proposing their prognostic capacity at primary diagnosis.

Clinical trial identification

Legal entity responsible for the study

TU Dresden.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.